Zimmer Biomet Holdings Inc. (NYSE:ZBH) went up by 2.05% from its latest closing price compared to the recent 1-year high of $161.11. The company’s stock price has collected 1.79% of gains in the last five trading sessions. Press Release reported on 09/10/20 that Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2020
Is It Worth Investing in Zimmer Biomet Holdings Inc. (NYSE :ZBH) Right Now?
Zimmer Biomet Holdings Inc. (NYSE:ZBH) scored a price-to-earnings ratio above its average ratio, recording 830.12 x from its present earnings ratio. Plus, the 36-month beta value for ZBH is at 1.33. Opinions of the stock are interesting as 19 analysts out of 28 who provided ratings for Zimmer Biomet Holdings Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 6 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $149.44, which is $13.3 above the current price. ZBH currently public float of 206.65M and currently shorts hold a 1.34% ratio of that float. Today, the average trading volume of ZBH was 1.10M shares.
ZBH’s Market Performance
ZBH stocks went up by 1.79% for the week, with a monthly drop of -3.36% and a quarterly performance of 14.08%, while its annual performance rate touched 1.89%. The volatility ratio for the week stands at 3.14% while the volatility levels for the past 30 days are set at 2.65% for Zimmer Biomet Holdings Inc.. The simple moving average for the period of the last 20 days is -1.80% for ZBH stocks with a simple moving average of 4.24% for the last 200 days.
Analysts’ Opinion of ZBH
Many brokerage firms have already submitted their reports for ZBH stocks, with Wolfe Research repeating the rating for ZBH by listing it as a “Outperform.” The predicted price for ZBH in the upcoming period, according to Wolfe Research is $174 based on the research report published on September 11th of the current year 2020.
Needham, on the other hand, stated in their research note that they expect to see ZBH reach a price target of $162, previously predicting the price at $148. The rating they have provided for ZBH stocks is “Strong Buy” according to the report published on August 05th, 2020.
ZBH Trading at -0.93% from the 50-Day Moving Average
After a stumble in the market that brought ZBH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.50% of loss for the given period.
Volatility was left at 2.65%, however, over the last 30 days, the volatility rate increased by 3.14%, as shares sank -3.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.72% upper at present.
During the last 5 trading sessions, ZBH rose by +1.79%, which changed the moving average for the period of 200-days by -8.06% in comparison to the 20-day moving average, which settled at $138.42. In addition, Zimmer Biomet Holdings Inc. saw -9.05% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ZBH starting from Yi Sang, who sale 3,000 shares at the price of $125.38 back on May 29. After this action, Yi Sang now owns 2,506 shares of Zimmer Biomet Holdings Inc., valued at $376,130 using the latest closing price.
Hanson Bryan C, the President and CEO of Zimmer Biomet Holdings Inc., purchase 1,000 shares at $113.00 during a trade that took place back on May 13, which means that Hanson Bryan C is holding 54,568 shares at $113,000 based on the most recent closing price.
Stock Fundamentals for ZBH
Current profitability levels for the company are sitting at:
- +15.13 for the present operating margin
- +63.98 for the gross margin
The net margin for Zimmer Biomet Holdings Inc. stands at +14.18. The total capital return value is set at 5.88, while invested capital returns managed to touch 5.80. Equity return is now at value 0.30, with 0.10 for asset returns.
Based on Zimmer Biomet Holdings Inc. (ZBH), the company’s capital structure generated 68.62 points at debt to equity in total, while total debt to capital is 40.70. Total debt to assets is 34.50, with long-term debt to equity ratio resting at 56.00. Finally, the long-term debt to capital ratio is 33.21.
Currently, EBITDA for the company is 148.50M with total debt to EBITDA at 3.71. When we switch over and look at the enterprise to sales, we see a ratio of 4.86, with the company’s debt to enterprise value settled at 0.22. The receivables turnover for the company is 6.05 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.